Amgen can close Horizon deal by September if no ruling from courts on FTC suit
Amgen and Horizon’s $28 billion merger will be able to close on Sept. 15 if the Federal Trade Commission’s lawsuit to block the merger hasn’t been resolved by that time, the biotech giant said in a securities filing Thursday.
Until then, the deal will be blocked from consummation by court order. Amgen has said previously that it expects the deal to close by the end of the year, and CEO Robert Bradway has said that he’s “confident” the deal will complete despite the government’s objections.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters